

# PRIOR AUTHORIZATION REQUEST FORM Migalastat (Galafold®) / Fabry disease in adults

#### DECLARATION OF THE INSURED PERSON

DECEMBATION OF THE INSORED I	LNSON					
Section 1: Information about the par	ticipant and the pat	tient				
Name of participant	Insurance policy / certificate		Name of employer			
Name of patient	Date of birth (YYYY/MM/DD)		Telephone			
Address (house number and street name)	City/Town		Province	Postal code		
Section 2: Other prescription drug insurance policies						
Do you have other prescription drug insurance?			☐ Yes	□ No		
If so, please answer the following:						
What type of plan is it?			□ Private	☐ Public		
Have you ever submitted a claim for this drug to the other insurer?			☐ Yes	□ No		
		☐ Accepted	☐ Refused	☐ Under review		
Did this insurer ask you to complete a prior authorization request?			☐ Yes	□ No		
If so, what is the status of the prior authorization request?		☐ Accepted	☐ Refused	☐ Under review		
Please enclose acceptance or refusal documents, if applicable						
Section 3: Authorization to disclose	personal information	n				
I certify that the information in this prior authorization request is complete, accurate and true.						
I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de I 'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my personal information including and without limitation any medical information and medical evaluations in connection with the processing of this request.  Photocopies of this document have the same value as the original.						
Signature of <b>patient</b> (parent/legal guardian) Date Date						
Signature of <b>patient</b> (parent/legal guardian) Date						
IMPORTANT:						
All correspondence concerning this form will be sent to the address indicated in the participant's file.						
Send us this duly completed form by mail or by fax to: 1-855-453-3942.						
Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6						
ssq.ca						



## PRIOR AUTHORIZATION REQUEST FORM Migalastat (Galafold®) / Fabry disease in adults

### **DECLARATION OF THE PHYSICIAN**

Section 4: Information a	bout the prescribing physi	cian					
Name of physician		Specialty		Licence No.:			
Telephone			Fax				
I hereby certify that the	information in this reques	t is complete, true	and accura	te:			
Signature of <b>physician</b> _		Date					
Section 5 : Drug covered							
Name of drug	Pharmaceutical form	Strength	Dosage				
			Dose:				
			Frequency of administration:				
Type of request	☐ First request		Continuation of treatment				
	Complete section 6		Complete section 7				
			Also complete section 6 if this is the first authorization requested from SSQ				
Section 6 : Clinical inform	nation (first request)						
Diagnostic :							
☐ Adult with a confirmed diagnosis of Fabry disease							
☐ Other. Specify:							
Mutation in the alpha g	alactosidase A coding gen	e that is recognize	ed amenahl	e to migalastat			
Mutation in the alpha galactosidase A coding gene that is recognized amenable to migalastat    Yes							
☐ No							
Show symptoms of the	disease including at least	renal cardiac or i	neurologica	l imnairment			
Show symptoms of the disease, including at least renal, cardiac or neurological impairment							
☐ Yes ☐ No							
Migalastat administration	on:						
_	in concomitance with an	enzyme treatmen	t replaceme	ent therapy			
□ Yes							



# PRIOR AUTHORIZATION REQUEST FORM Migalastat (Galafold®) / Fabry disease in adults

Section 7 : Clinical information (continuation of treatment)
Beneficial effects observed
Treatment start date (YYYY-MM-DD):
☐ Beneficial effects on the manifestations that justified the initiation of the treatment
☐ Absence of the disease progression
Other. Specify:
Section 8 : Additional information